Prediction of pathological stage based on clinical stage, serum prostate‐specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era

To update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past three decades.

[1]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[2]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Tosoian,et al.  Active surveillance for prostate cancer: current evidence and contemporary state of practice , 2016, Nature Reviews Urology.

[4]  P. Dasgupta,et al.  Immune checkpoint blockade – a treatment for urological cancers? , 2016, BJU international.

[5]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[6]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[7]  Michael Laviolette,et al.  Trends in initial management of prostate cancer in New Hampshire , 2015, Cancer Causes & Control.

[8]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[9]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[10]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[11]  K. Badani,et al.  Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices. , 2015, Urology.

[12]  S. Boorjian,et al.  Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. , 2015, Urologic oncology.

[13]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[14]  Ziding Feng,et al.  Prediction of patient‐specific risk and percentile cohort risk of pathological stage outcome using continuous prostate‐specific antigen measurement, clinical stage and biopsy Gleason score , 2011, BJU international.

[15]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[16]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[17]  V. Laudone,et al.  Reverse stage shift at a tertiary care center , 2011, Cancer.

[18]  Alan W Partin,et al.  Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .

[19]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[20]  T. Skolarus,et al.  Expectant management of veterans with early‐stage prostate cancer , 2016, Cancer.

[21]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[22]  Jennifer L. Beebe-Dimmer,et al.  Prognostic Gleason grade grouping : data based on the modified Gleason scoring system , 2013 .

[23]  S. Woolf.  United States preventive services task force recommendations on breast cancer screening , 1992, Cancer.

[24]  A. Haese*,et al.  Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade , 2011, BJU international.

[25]  F. Montorsi,et al.  Natural history of surgically treated high-risk prostate cancer. , 2015, Urologic oncology.

[26]  James M Henning,et al.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. , 2002, The Journal of urology.

[27]  M. Soloway,et al.  Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. , 2008, Urology.

[28]  E. Schaeffer,et al.  Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience , 2015, The Prostate.

[29]  Mufaddal Mamawala,et al.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[31]  Hartwig Huland,et al.  Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment? , 2015, European urology.

[32]  A. Jemal,et al.  Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. , 2015, JAMA.

[33]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[34]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[35]  Alan W Partin,et al.  Validation of the partin nomogram for prostate cancer in a national sample. , 2010, The Journal of urology.

[36]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[37]  Validation of the novel International Society of Urological Pathology 2014 five‐tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimated , 2016, BJU international.

[38]  S. Eggener,et al.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Pierre I Karakiewicz,et al.  Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. , 2003, European urology.

[40]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[41]  M. Ballal,et al.  Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer? , 2005, BJU international.

[42]  P. Walsh,et al.  Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.

[43]  Ahmet Soylu,et al.  Validation of 2001 Partin tables in Turkey: a multicenter study. , 2005, European urology.

[44]  B. Trock,et al.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 , 2013, BJU international.